Fusion protein comprising the whole or part of the PP65 protein of human CMV, useable in particular for preparing a vaccine
US6605467B2 · kind B2 · utility
0Cited by
3References
14Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jul 6, 1999 |
| Grant date | Aug 12, 2003 |
| Priority date | — |
| Expiry date | Jul 6, 2019 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2710/16122
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention concerns a fusion protein characterised in that it comprises at least part of the pp65 protein of the cytomegalovirus (or CMV), or a protein having at least 80% homology with the pp65 protein, in combination with at least a second peptide fragment derived from CMV. The invention also concerns a nucleotide sequence coding for such a protein, or a pharmaceutical composition containing them. It further concerns its use as medicine and a method for preparing the protein.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.